← All Denali Therapeutics INC filings

Denali Therapeutics INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Q3 2025: DNL310 BLA Review Extended, ALS Trial Fails
Denali Therapeutics reports Q3 2025 financial results with increased net losses, DNL310 BLA review extension, and discontinuation of the DNL343 ALS trial.
NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Therapeutics Accelerates Key Programs
Denali Therapeutics reported increased Q2 losses but achieved significant clinical and regulatory milestones for its lead neurodegenerative and lysosomal storage disease programs.
NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Therapeutics Reports Q1 2025 Financial Results, Provides Business Update
Denali Therapeutics reports a net loss for Q1 2025, provides updates on clinical programs, and highlights financial position.
NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Therapeutics Reports Third Quarter 2024 Results, Advances Pipeline
Denali Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic initiatives.
NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Therapeutics Reports Second Quarter 2024 Results, Strategic Shift in Pipeline
Denali Therapeutics reports a net loss for Q2 2024, alongside a strategic divestiture of preclinical small molecule programs and a focus on TV-enabled platforms.
NASDAQ
DNLI
Denali Therapeutics INC
10-Q: Denali Therapeutics Reports First Quarter 2024 Results, Highlights Strategic Shift and Financial Update
Denali Therapeutics reports a net loss of $101.8 million for Q1 2024, alongside a strategic divestiture of preclinical small molecule programs and a significant capital raise.